First‐in‐Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection
dc.contributor.author | Flechner, S. M. | en_US |
dc.contributor.author | Mulgoankar, S. | en_US |
dc.contributor.author | Melton, L. B. | en_US |
dc.contributor.author | Waid, T. H. | en_US |
dc.contributor.author | Agarwal, A. | en_US |
dc.contributor.author | Miller, S. D. | en_US |
dc.contributor.author | Fokta, F. | en_US |
dc.contributor.author | Getts, M. T. | en_US |
dc.contributor.author | Frederick, T. J. | en_US |
dc.contributor.author | Herrman, J. J. | en_US |
dc.contributor.author | Puisis, J. P. | en_US |
dc.contributor.author | O'Toole, L. | en_US |
dc.contributor.author | Sung, R. | en_US |
dc.contributor.author | Shihab, F. | en_US |
dc.contributor.author | Wiseman, A. C. | en_US |
dc.contributor.author | Getts, D. R. | en_US |
dc.date.accessioned | 2014-06-04T14:57:08Z | |
dc.date.available | WITHHELD_13_MONTHS | en_US |
dc.date.available | 2014-06-04T14:57:08Z | |
dc.date.issued | 2014-06 | en_US |
dc.identifier.citation | Flechner, S. M.; Mulgoankar, S.; Melton, L. B.; Waid, T. H.; Agarwal, A.; Miller, S. D.; Fokta, F.; Getts, M. T.; Frederick, T. J.; Herrman, J. J.; Puisis, J. P.; O'Toole, L.; Sung, R.; Shihab, F.; Wiseman, A. C.; Getts, D. R. (2014). "First‐in‐Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection." American Journal of Transplantation 14(6): 1346-1355. | en_US |
dc.identifier.issn | 1600-6135 | en_US |
dc.identifier.issn | 1600-6143 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/107383 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Induction | en_US |
dc.subject.other | Acute Rejection | en_US |
dc.subject.other | Kidney Transplantation | en_US |
dc.title | First‐in‐Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/107383/1/ajt12698.pdf | |
dc.identifier.doi | 10.1111/ajt.12698 | en_US |
dc.identifier.source | American Journal of Transplantation | en_US |
dc.identifier.citedreference | Sempe P, Bedossa P, Richard MF, Villa MC, Bach JF, Boitard C. Anti‐alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur J Immunol 1991; 21: 1163 – 1169. | en_US |
dc.identifier.citedreference | Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451 – 1462. | en_US |
dc.identifier.citedreference | Dierselhuis M, Goulmy E. The relevance of minor histocompatibility antigens in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 419 – 425. | en_US |
dc.identifier.citedreference | Archbold JK, Ely LK, Kjer‐Nielsen L, et al. T cell allorecognition and MHC restriction—A case of Jekyll and Hyde ? Mol Immunol 2008; 45: 583 – 598. | en_US |
dc.identifier.citedreference | Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715 – 2729. | en_US |
dc.identifier.citedreference | Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770 – 781. | en_US |
dc.identifier.citedreference | Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus based therapy without calcineurin inhibitors. Transplantation 2009; 87: S1 – S6. | en_US |
dc.identifier.citedreference | Webster AC, Playforde G, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta‐analysis of randomized trials. Transplantation 2004; 77: 166 – 176. | en_US |
dc.identifier.citedreference | Patlola V, Zhong X, Reed GW, Mandelbrot DA. Efficacy of anti‐IL‐2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 2007; 7: 1832 – 1841. | en_US |
dc.identifier.citedreference | Cai J, Terasaki PI. Induction immunosuppression improves long‐term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511 – 1515. | en_US |
dc.identifier.citedreference | Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin‐inhibitor immunosuppressive regimens. Biodrugs 2005; 19: 39 – 46. | en_US |
dc.identifier.citedreference | Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients: How convincing is the current evidence ? Drugs 2012; 72: 671 – 683. | en_US |
dc.identifier.citedreference | Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967 – 1977. | en_US |
dc.identifier.citedreference | Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909 – 1919. | en_US |
dc.identifier.citedreference | Guttmann RD, Caudrelier P, Alberici G, Touraine JL. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997; 29: 24S – 26S. | en_US |
dc.identifier.citedreference | Broeders N, Wissing KM, Crusiaux A, Kinnaert P, Vereerstraeten P, Abramowicz D. Mycophenolate mofetil, together with cyclosporin A, prevents anti‐OKT3 antibody response in kidney transplant recipients. J Am Soc Nephrol 1998; 9: 1521 – 1525. | en_US |
dc.identifier.citedreference | Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone‐free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction—Long‐term results. Am J Transplant 2005; 5: 2539 – 2548. | en_US |
dc.identifier.citedreference | Matsumoto Y, Tsuchida M, Hanawa H, Abo T. Successful prevention and treatment of autoimmune encephalomyelitis by short‐term administration of anti‐T‐cell receptor alpha beta antibody. Immunology 1994; 81: 1 – 7. | en_US |
dc.identifier.citedreference | Khariwala SS, Knott PD, Dan O, Klimczak A, Siemionow M, Strome M. Pulsed immunosuppression with everolimus and anti‐alphabeta T‐cell receptor: Laryngeal allograft preservation at six months. Ann Otol Rhinol Laryngol 2006; 115: 74 – 80. | en_US |
dc.identifier.citedreference | Siemionow MZ, Izycki DM, Zielinski M. Donor‐specific tolerance in fully major histocompatibility major histocompatibility complex‐mismatched limb allograft transplants under an anti‐alphabeta T‐cell receptor monoclonal antibody and cyclosporine A protocol. Transplantation 2003; 76: 1662 – 1668. | en_US |
dc.identifier.citedreference | Waid TH, Lucas BA, Thompson JS, et al. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: Final analysis of a phase II clinical trial. Transplantation 1997; 64: 274 – 281. | en_US |
dc.identifier.citedreference | Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A‐31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80 – 86. | en_US |
dc.identifier.citedreference | Beelen DW, Graeven U, Schulz G, et al. Treatment of acute graft‐versus‐host disease after HLA‐partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase‐I/II trial. Onkologie 1988; 11: 56 – 58. | en_US |
dc.identifier.citedreference | Haynes BF, Fauci AS. The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus‐derived lymphocytes. J Clin Invest 1978; 61: 703 – 707. | en_US |
dc.identifier.citedreference | Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies ? MAbs 2010; 2: 682 – 694. | en_US |
dc.identifier.citedreference | Flechner SM, Goldfarb DA, Fairchild R, et al. A randomized prospective trial of low dose OKT3 to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation 2000; 69: 2374 – 2381. | en_US |
dc.identifier.citedreference | Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193 – 1198. | en_US |
dc.identifier.citedreference | Getts DR, Shankar S, Chastain EM, et al. Current landscape for T‐cell targeting in autoimmunity and transplantation. Immunotherapy 2011; 3: 853 – 870. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.